Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled time : 15:30 source : Www.atossatherapeutics.com save search
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022
Published: 2022-01-27 (Crawled : 15:30) - atossatherapeutics.com
ATOS | $1.485 4.58% 4.38% 1.1M
|
Health Technology
|
| O: 0.79%
H: 2.24%
C: -5.51%
ceo therapeutics
Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201
Published: 2022-01-18 (Crawled : 15:30) - atossatherapeutics.com
ATOS | $1.485 4.58% 4.38% 1.1M
|
Health Technology
|
| O: -2.05%
H: 2.8%
C: -2.8%
ces therapeutics
Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden
Published: 2021-12-22 (Crawled : 15:30) - atossatherapeutics.com
ATOS | $1.485 4.58% 4.38% 1.1M
|
Health Technology
|
| O: -1.08%
H: 1.63%
C: 0.0%
phase 2 therapeutics enroll
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.